Calidi Biotherapeutics (CLDI) Free Cash Flow (2022 - 2025)

Calidi Biotherapeutics has reported Free Cash Flow for 4 years, with the latest figure at -$5.1 million in Q4 2025.

• For the quarter ending Q4 2025, Free Cash Flow rose 5.64% year-over-year to -$5.1 million; the trailing twelve-month figure through Dec 2025 stood at -$21.4 million (down 8.64% YoY), and the FY2025 full-year result was -$21.4 million, down 8.64% from the prior year.
• Free Cash Flow for Q4 2025 stood at -$5.1 million, down from -$4.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$268679.0 in Q2 2022, with the low at -$14.0 million in Q3 2023.
• Average Free Cash Flow over 4 years is -$5.1 million, with a median of -$5.0 million recorded in 2023.
• Year-over-year, Free Cash Flow tumbled 1784.03% in 2023 and surged 64.64% in 2024.
• Tracing CLDI's Free Cash Flow over 4 years: stood at -$4.0 million in 2022, then tumbled by 30.2% to -$5.3 million in 2023, then dropped by 3.27% to -$5.4 million in 2024, then advanced by 5.64% to -$5.1 million in 2025.
• The last three Free Cash Flow figures came in at -$5.1 million (Q4 2025), -$4.2 million (Q3 2025), and -$5.0 million (Q2 2025), per Business Quant data.

Peer Comparison